CELGENE CORPORATION

Form 483 issued June 16, 2023 · SUMMIT, New Jersey

Inspection
Jun 5 – Jun 16, 2023
Investigator
Helen B. Ricalde
Observations
4
Pages
4
FEI number
3004991673

In short: On June 16, 2023, FDA issued a Form 483 with 4 observations to CELGENE CORPORATION in SUMMIT, New Jersey (FEI 3004991673) after an inspection that ran Jun 5 – Jun 16, 2023. The investigator was Helen B. Ricalde. Most observations concern facilities & equipment and packaging & labeling; the most-cited regulation is 21 CFR 211.42 (design and construction features).

At a glance

Facilities & equipment and packaging & labeling account for 3 of 4 observations.

Facilities & equipment2
Packaging & labeling1
Production1

What FDA observed

Preview: the opening words of each observation
  1. 01

    Drug products do not bear an expiration date determined by appropriate stability data to assure they…

  2. 02

    Your firm failed to establish adequate written procedures for production and process controls designed to assure…

  3. 03

    Aseptic processing areas are deficient regarding the system…

  4. 04

    Separate or defined areas to prevent contamination or mix-ups are deficient regarding the…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at CELGENE CORPORATION?

FDA listed 4 observations on this Form 483, mostly about facilities & equipment, packaging & labeling and production. The most-cited regulation is 21 CFR 211.42 (design and construction features). The opening words of each observation are shown on this page.

Who inspected CELGENE CORPORATION?

Helen B. Ricalde is named on this Form 483, for the inspection of Jun 5 – Jun 16, 2023. Each investigator has a profile showing what they cite most.

When was CELGENE CORPORATION inspected by FDA?

The inspection ran Jun 5 – Jun 16, 2023, and the Form 483 is dated June 16, 2023.

How do I get the full Form 483 for CELGENE CORPORATION?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free